Skip Navigation LinksHome > November 2012 - Volume 7 - Issue 6 > Cost–effectiveness of pre-exposure prophylaxis for HIV: a r...
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e3283582c8b

Cost–effectiveness of pre-exposure prophylaxis for HIV: a review

Schackman, Bruce R.; Eggman, Ashley A.

Collapse Box


Purpose of review: The US Food and Drug Administration (FDA) recently approved the use of tenofovir–emtricitabine for pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP is also being investigated in clinical trials as a component of HIV prevention in resource-limited settings. Cost–effectiveness models are useful in identifying health programs with the greatest societal value and projecting long-term program impacts. This review examines six recent studies of the cost–effectiveness of PrEP for preventing HIV transmission in the USA and South Africa.

Recent findings: Studies used both individual-level and population-level transmission models. PrEP was found to be a cost-effective HIV-prevention intervention in high-risk MSM with HIV incidence at least 2% in the USA (<US$100 000 per quality-adjusted life year) and in young women in South Africa (cost per life year <GDP per capita). Results were sensitive to the cost and efficacy of PrEP and to assumptions about HIV testing and access to treatment in the absence of PrEP.

Summary: Future cost effectiveness studies should consider PrEP implementation issues (uptake in high-risk versus low-risk groups, duration on PrEP, adherence), budget impact, and the role of PrEP as part of combination HIV-prevention strategies including expanded testing and treatment access.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.